Skip to content
    INCY
    Earnings call· Mar 2026(Q1 FY26)

    INCYTE Q1 FY26 earnings call INCY

    Apr 28, 2026 Source

    Executive summary

    Incyte Q1 FY26 — Strong Portfolio Growth and Pipeline Advancement

    Incyte delivered a strong first quarter, marked by robust sales growth across its commercial portfolio and significant advancements in its late-stage pipeline. The company is strategically transitioning beyond its cornerstone product, Jakafi, towards a diversified portfolio in hematology, oncology, and immunology. Key regulatory and clinical milestones were achieved, including the FDA acceptance of povorcitinib's NDA for HS and positive Phase III data for povorcitinib in nonsegmental vitiligo, positioning Incyte for multiple potential launches and continued long-term growth.

    Highlights

    5
    • Total revenue increased 21% year-over-year to $1.27 billion.

    • Net sales grew 20% year-over-year to $1.1 billion, driven by strong demand across the portfolio.

    • Core business excluding Jakafi sales were up 63% year-over-year.

    • Opzelura sales increased 20% year-over-year to $143 million, with US prescription demand up 17%.

    • Povorcitinib NDA for moderate to severe HS accepted by FDA ahead of schedule, with positive Phase III results for nonsegmental vitiligo announced.

    Guidance & targets

    16
    CategoryTargetConfidence
    Full-year 2026 Total Net Sales
    $4.77 billion to $4.94 billion
    high materiality
    High
    Full-year 2026 Jakafi Net Sales
    $3.22 billion to $3.27 billion
    high materiality
    High
    Full-year 2026 Opzelura Net Sales
    $750 million to $790 million
    high materiality
    High
    Full-year 2026 Hematology and Oncology Products Net Sales
    $800 million to $880 million
    high materiality
    High
    Full-year 2026 Total GAAP R&D and SG&A Operating Expenses
    $3.495 billion to $3.675 billion
    medium materiality
    High
    Jakafi XR Business Contribution
    10% to 30% of Jakafi's business
    medium materiality
    Medium
    Core Business ex-Jakafi Revenue
    approach $3 billion to $4 billion
    high materiality
    Medium
    I&I Portfolio Revenue Contribution
    approximately 1/3 of total revenue
    medium materiality
    Medium
    Monjuvi First-Line DLBCL Approval and Launch
    early 2027
    medium materiality
    Medium
    Povorcitinib HS Approval and Launch
    early 2027
    high materiality
    Medium
    Povorcitinib Nonsegmental Vitiligo Regulatory Application
    first half of 2027
    medium materiality
    Medium
    989 Phase III Study Initiation in ET
    midyear
    medium materiality
    High
    989 Phase III Study Initiation in MF
    second half of 2026
    medium materiality
    Medium
    667 Phase III Study Initiation in Ovarian Cancer
    second half of 2026
    medium materiality
    Medium
    Opzelura Moderate AD Europe Approval and Launch
    second half of the year
    medium materiality
    Medium
    Jakafi XR Approval and Launch
    middle of the year
    medium materiality
    High

    Segment performance

    11
    SegmentRevenueYoYQoQMargin
    Total Company
    Total revenue for the first quarter of 2026.
    $1.27B21%
    Net Sales
    Net sales for the first quarter of 2026, driven by strong prescription and volume demand.
    $1.1B20%
    Jakafi
    Strong sales driven by broad-based growth and strong new patient starts.
    Prescription demand: 6% increaseBroad-based growth across all indications: MF, PV, GVHD
    $758M7%
    Core Business ex-Jakafi
    Significant growth from contributions across hematology, oncology, and immunology.
    63%
    Opzelura
    Largest single contributor to the core business ex-Jakafi.
    $143M20%
    Opzelura US
    Sales growth supported by continued adoption of nonsteroidal topical therapies.
    Underlying prescription demand: 17% increase year-over-year
    $106M12%
    Opzelura International
    Robust growth in vitiligo internationally.
    Strong uptake across markets in vitiligo
    $37M56%
    Hematology and Oncology
    Growth primarily driven by Niktimvo, Monjuvi, and Zynyz.
    $204M116%
    Niktimvo
    Entered its second year post-launch with broad and growing prescriber base.
    Strong consistent new patient start profileSolid persistency3rd line+ market share: 32%
    $55M
    Monjuvi
    Growth primarily driven by uptake in follicular lymphoma.
    $49M67%
    Zynyz
    Rapid and robust adoption in SCAC.
    $41M

    Operational metrics

    28
    GAAP R&D expenses
    $516M18% increase YoY
    Q1 FY26

    Driven by continued investment in late-stage development assets.

    GAAP SG&A expenses
    $328M1% increase YoY
    Q1 FY26

    Operating expenses for the quarter.

    Cost of sales
    9%relatively stable
    FY26

    Anticipated to remain stable for the full year.

    Vitiligo US Market Size
    1.5M
    current

    Number of people living with vitiligo in the US.

    Vitiligo Treatment Seeking Patients
    20% to 30%
    current

    Percentage of vitiligo patients who seek treatment.

    Opzelura Vitiligo Patient Segment (BSA < 5%)
    35%
    current

    Percentage of vitiligo patients with BSA less than 5%, suitable for Opzelura.

    Opzelura Vitiligo Patient Segment (BSA 5-10%)
    target patient population
    current

    Patient segment between 5% and 10% BSA also targeted by Opzelura.

    Povorcitinib Vitiligo Patient Segment (BSA > 10%)
    most likely for systemic therapy
    current

    Patient segment with BSA greater than 10%, where systemic therapy is most likely.

    Vitiligo Total Addressable Market
    $1.5B to $2B
    current

    Estimated total addressable market for vitiligo, giving povorcitinib a great opportunity.

    Opzelura CAGR
    10% to 15%
    next 5 years

    Anticipated compound annual growth rate for Opzelura.

    Opzelura New Patient Starts Share
    46%
    Q1 FY26

    Share of new patient starts in the US market for Opzelura.

    Opzelura New Patient Starts Volume Growth
    over 30%YoY
    Q1 FY26

    Growth in new patient start volume for Opzelura in the US.

    989 ET Patients Enrolled (EHA Update)
    approximately 100
    EHA update

    Number of ET patients for whom data will be reported at EHA.

    989 MF Patients Enrolled (EHA Update)
    about 45
    EHA update

    Number of MF patients (single agent) for whom data will be reported at EHA.

    989 MF Combo Patients Enrolled (EHA Update)
    about 15 to 16
    EHA update

    Number of MF patients (in combination with ruxolitinib) for whom data will be reported at EHA.

    734 Pneumonitis Cases
    4out of >350 patients
    program review

    Number of pneumonitis events observed in the 734 program, with 3 in combination with chemotherapy and 2 with concurrent infections.

    PDAC G12D Mutation Prevalence
    40%
    current

    Percentage of pancreatic ductal adenocarcinoma patients with G12D mutation.

    HS US Market Size
    300,000
    current

    Number of people affected by HS in the United States.

    HS Patients Actively Seeking Treatment
    200,000
    current

    Number of HS patients actively seeking treatment in the US.

    HS Patients on Advanced Therapy
    50,000
    current

    Number of HS patients currently on advanced therapy.

    Povorcitinib HS Peak Sales Potential
    $500M to $1B
    peak

    Estimated peak sales potential for povorcitinib in HS.

    Povorcitinib HS HiSCR50 at Week 54
    up to 71%
    Week 54

    Percentage of patients achieving HiSCR50 with long-term povorcitinib treatment.

    Povorcitinib HS HiSCR75 at Week 54
    up to 57%
    Week 54

    Percentage of patients achieving HiSCR75 with long-term povorcitinib treatment.

    Povorcitinib HS HiSCR100 at Week 54
    up to 29%
    Week 54

    Percentage of patients achieving HiSCR100 (complete clearance) with long-term povorcitinib treatment.

    Povorcitinib HS Draining Tunnels Clearance at Week 54
    up to 20%
    Week 54

    Percentage of patients achieving complete clearance of draining tunnels and nodules.

    Povorcitinib Vitiligo F-VASI Reduction
    greater than or equal to 75%vs placebo
    Week 52

    Primary endpoint achieved in Phase III studies, demonstrating statistically significant and clinically meaningful reductions in facial vitiligo.

    Povorcitinib Vitiligo T-VASI 50
    statistically significant improvements
    Week 52

    Improvements observed in key secondary endpoint measures.

    Povorcitinib Vitiligo TEAEs of Special Interest
    2% and 3%similar between groups
    52 weeks

    Low rates of treatment-emergent adverse events of special interest, consistent with prior studies.

    Industry KPIs

    5
    MetricValueDetails
    Launch access metricsstrong
    Peak long term sales guidance10% to 30%%
    Therapeutic drug market share32%%
    Prescription volume new starts6%%
    Clinical trial efficacy safety dataup to 71%%

    Product announcements

    1
    ProductTypeDetails
    Zynyzexpansion

    What to watch in Q2 FY26

    5

    989 ET Phase III Initiation

    mid-CY26
    CurrentOn track for midyear
    TargetInitiated

    Why it matters

    Initiation of this pivotal trial is a key step in building a portfolio of molecularly targeted therapies for ET.

    we are on track to initiate our Phase III study in evaluating our mutant CALR antibody 989 in previously treated CALR positive patients with ET by midyear.

    Q&A highlights

    8

    How will povorcitinib coexist with Opzelura in the vitiligo market, and what has been the experience with marketing in this indication so far? Will they appeal to different patient segments?

    Management believes povorcitinib and Opzelura offer a 'topical to oral' solution, covering the full spectrum of vitiligo patients. Opzelura targets patients with BSA less than 10%, while povorcitinib is suited for those with BSA greater than 10% who need systemic therapy. This continuum positions Incyte uniquely to address the entire patient journey and medicalize the condition, which has a total addressable market of $1.5 billion to $2 billion.

    This is definitely about medicalizing the condition. Frankly, I think Incyte does have an advantage in that we have a topical to oral solution. There is a natural sequencing that sets up in the vitiligo market and we're able to cover sort of the waterfront with both Opzelura as well as with povorcitinib.

    asked by Tazeen Ahmad · answered by William Meury

    3 min read6 chapters

    Detailed Narrative

    01

    Strategic Transition and Portfolio Diversification

    Incyte is undergoing a strategic transition to evolve beyond its cornerstone product, Jakafi, aiming for a high-quality, growth-oriented portfolio across hematology, oncology, and immunology. This involves continued organic growth from existing commercial products, life cycle launches of key brands, advancement of a broad late-stage pipeline, and a focused approach to business development. The company expects its I&I portfolio to contribute approximately one-third of total revenue by 2030, and the core business ex-Jakafi to approach $3 billion to $4 billion by the same year.

    02

    Povorcitinib Advancements in HS and Vitiligo

    The FDA accepted the regulatory application for povorcitinib in moderate to severe hidradenitis suppurativa (HS) ahead of schedule, supported by robust Phase III data in both pre- and post-biologic patient populations. Positive results were also announced from two Phase III studies for povorcitinib in nonsegmental vitiligo, demonstrating statistically significant and clinically meaningful reductions in facial vitiligo. These results will support a regulatory application in H1 2027, with potential approvals and launches in early 2027 for HS and vitiligo, positioning povorcitinib as a significant growth driver.

    03

    Pipeline Progress in Hematology and Oncology

    In hematology, Incyte is on track to initiate a Phase III study for 989 (mutant CALR antibody) in previously treated ET patients by midyear, following a positive end-of-phase meeting with the FDA. The company also initiated a Phase I dose escalation study for 058 (JAK2 V617F inhibitor) ASD formulation in MPN patients. In oncology, a Phase III study for KRAS G12D inhibitor 734 in first-line pancreatic cancer is underway, targeting a significant unmet need. Additionally, pivotal trials are advancing for A90 in colorectal cancer and 667 in ovarian cancer.

    04

    Commercial Performance and Growth Drivers

    Total revenue for Q1 FY26 was $1.27 billion, up 21% year-over-year, with net sales of $1.1 billion, up 20%. Jakafi sales reached $758 million, a 7% increase, driven by broad growth across indications. The core business excluding Jakafi grew 63% year-over-year, with Opzelura contributing $143 million (up 20%). Niktimvo, Monjuvi, and Zynyz also showed strong growth, with Niktimvo capturing 32% of the third-line plus market within 12 months of launch.

    05

    Management Team Enhancements

    Incyte announced several executive appointments to strengthen its leadership team for the next phase of growth. Suky Upadhyay was appointed Chief Financial Officer, Pablo Cagnoni as President, Incyte and Global Head of Research and Development, and Steven Stein as Executive Vice President and Chief Medical Officer and Head of Late-stage Development. Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, coinciding with the integration of U.S. commercial operations to create a launch-ready organization.

    06

    Opzelura's Market Position and Future

    Opzelura continues to be a major contributor, with strong US prescription demand up 17% year-over-year and international growth robust in vitiligo. The brand is under review in Europe for moderate AD, with approval and launch expected in H2 2026. Management believes Opzelura can achieve approximately $1.3 billion in sales by 2030, driven by continued penetration in AD and vitiligo, the upcoming launch in mild to moderate HS, and European expansion.

    AI-generated summary of the company’s earnings call. Not investment advice.